Verrica Pharmaceuticals
Verrica Pharmaceuticals' revenue rose 370.2% to $36 million in fiscal 2025. Its operating margin was −34.2%, up from −871.2% a year earlier. Free cash flow was −$18 million. The diluted share count rose 105.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Verrica Pharmaceuticals lost money in fiscal 2025: a net loss of $18 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 70 | 34 | 70 | 46 | 30 |
| Debt incl. finance leases | — | 0 | 44 | 32 | 1 |
| Net debt (negative means net cash) | — | −34 | −25 | −14 | −29 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | 2.2x | — | 0.0x |
| Interest coverage | −7.2x | −9.8x | −16.6x | −7.0x | −1.6x |
| Current ratio | 1.6x | 11.3x | 4.5x | 1.8x | 2.6x |
| Quick ratio | 1.6x | 11.3x | 4.5x | 1.7x | 2.5x |
Cash flow
Projections
Project Verrica Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $18.2 million of Verrica Pharmaceuticals shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | John J. KirbyInterim CFO | Bought | 5,000 | $4.93 | $24,650 | Form 4 |
| Aug 18, 2026 | Noah L. RosenbergCMO | Bought | 2,030 | $4.92 | $9,988 | Form 4 |
| Aug 17, 2026 | David ZawitzChief Operating Officer | Bought | 6,000 | $4.98 | $29,880 | Form 4 |
| Aug 17, 2026 | Jayson RiegerCEO and President, Director | Bought | 5,000 | $4.91 | $24,550 | Form 4 |
| Aug 17, 2026 | Noah L. RosenbergCMO | Bought | 4,200 | $4.91 | $20,622 | Form 4 |
| Aug 14, 2026 | Jayson RiegerCEO and President, Director | Bought | 20,000 | $5.06 | $101,200 | Form 4 |
| Nov 25, 2025 | Paul B ManningDirector, 10% owner | Bought | 4,126,142 | $4.24 | $17.5 million | Form 4 |
| Nov 25, 2025 | Jayson RiegerCEO and President, Director | Bought | 94,311 | $4.24 | $399,879 | Form 4 |
| Nov 25, 2025 | David ZawitzChief Operating Officer | Bought | 10,000 | $4.24 | $42,400 | Form 4 |
| Nov 25, 2025 | John J. KirbyInterim CFO | Bought | 3,536 | $4.24 | $14,993 | Form 4 |
| Nov 25, 2025 | Noah L. RosenbergCMO | Bought | 2,357 | $4.24 | $9,994 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 3 of 9 | 5 of 8 |
| Rule of 40 | −803.2% | −758.0% | 320.7% |
| Altman Z'' | −9.42 | −24.15 | −19.42 |
| Accruals ratio | −45.0% | −23.1% | −0.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Fail | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 2 of 8 | 3 of 9 | 5 of 8 |
Compare
Put Verrica Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals | FY25 | 370.2% | −34.2% | −49.5% | — | — | 5 | |
| BGM Group | FY25 | 51.1% | −33.2% | −10.4% | — | — | — | Compare |
| Nanobiotix | FY25 | — | −33.2% | −104.2% | — | — | — | Compare |
| EyePoint | FY25 | −27.5% | −776.0% | −775.8% | — | — | — | Compare |
| Foghorn Therapeutics | FY25 | 36.8% | −279.5% | −278.7% | — | — | 2 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | 12 | 9 | 5 | 8 | 36 |
| Revenue growth | — | — | — | — | — | −24.7% | −43.3% | 47.7% | 370.2% |
| Gross profit | — | — | — | — | — | — | 5 | 5 | — |
| Research and development | 4 | 13 | 15 | 16 | 16 | 12 | 20 | 12 | 9 |
| Operating income | −4 | −22 | −30 | −40 | −31 | −21 | −66 | −66 | −12 |
| Net income | −4 | −21 | −28 | −43 | −35 | −24 | −67 | −77 | −18 |
| Diluted EPS (US$) | −15.60 | −14.10 | −11.30 | −17.10 | −13.00 | −7.20 | −14.80 | −14.78 | −1.68 |
| Diluted shares (millions) | 0 | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 11 |
| Cash flow | |||||||||
| Cash from operations | −5 | −18 | −27 | −30 | −28 | −19 | −39 | −61 | −18 |
| Capital expenditure | — | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | — | −19 | −28 | −32 | −28 | −19 | −39 | −61 | −18 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 3 | 10 | 6 | 5 | 14 | 7 | 3 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 9 | 10 | 9 | 11 | 70 | 34 | 70 | 46 | 30 |
| Debt incl. finance leases | — | — | — | — | — | 0 | 44 | 32 | 1 |
| Total assets | 9 | 92 | 68 | 74 | 80 | 45 | 82 | 54 | 47 |
| Total liabilities | 1 | 2 | 3 | 41 | 48 | 5 | 62 | 64 | 22 |
| Shareholders' equity | −7 | 89 | 65 | 33 | 33 | 40 | 20 | −10 | 25 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | 90.2% | 65.6% | — |
| Operating margin | — | — | — | — | −257.6% | −235.8% | −1,283.3% | −871.2% | −34.2% |
| Net margin | — | — | — | — | −292.3% | −271.1% | −1,307.5% | −1,012.1% | −50.3% |
| Free cash flow margin | — | — | — | — | −237.2% | −209.8% | −759.9% | −805.6% | −49.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −234.6% | −803.2% | −758.0% | 320.7% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −50.1% | −36.5% | −87.1% | −107.0% | −67.4% | −224.1% | −1,546.6% | −240.3% |
| Return on assets | — | −40.9% | −35.2% | −59.9% | −45.5% | −39.2% | −106.1% | −112.8% | −35.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |